ClinicalTrials.gg
RecruitingNCT06563414Updated Jul 2, 2025

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

An observational study in Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive and Epidermolysis Bullosa Dystrophica Dominans, sponsored by Krystal Biotech, Inc.. Recruiting at 1 site in United States. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Krystal Biotech, Inc. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
40
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States — 13 open to participants now, 17 under way, 4 of them phase 3. Epidermolysis Bullosa Dystrophica · United States.

Planned enrollment
6th of 13
40 · median 29
Started
2024
with 2 others
Observational
13 of 46
6 open now
Primary completion
2025-12
later than 5 of 16 live
Registered
39th of 46
by date
Lead sponsor
7 of 46
Krystal Biotech, Inc.

Among the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States, this one is the 6th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 5 of the 16 other live ones, and was the 39th registered.

Epidermolysis Bullosa Dystrophica

79 studies on the registry are indexed under Epidermolysis Bullosa Dystrophica; 22 are open to participants now.

Browse Epidermolysis Bullosa Dystrophica studies →

Open to participants now

13 of the 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Epidermolysis Bullosa Dystrophica studies recruiting now, 13 (76%) set no upper age limit and 3 (18%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Epidermolysis Bullosa Dystrophica with a site in United States, or all of them as a file.
02

Study summary

This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).

Read the detailed description

The objective of this study is to characterize the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB). Patients will be followed via remote weekly symptom diaries and monthly questionnaires to assess corneal abrasion symptoms, frequency, and duration.

03

Conditions studied

  • Epidermolysis Bullosa Dystrophica
  • Epidermolysis Bullosa Dystrophica, Recessive
  • Epidermolysis Bullosa Dystrophica Dominans

Keywords

  • Dystrophic Epidermolysis Bullosa
  • DEB
  • Corneal Abrasions
04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Dystrophic Epidermolysis Bullosa, aged 6 months or older.

Eligibility criteria

Inclusion Criteria:

  1. The subject or their respective legal guardian must have read, understood, and signed an Institutional Review Board (IRB) approved /Assent Form and must be able to and willing to follow study procedures and instructions.
  2. Age 6 months or older at time of Informed Consent/Assent.
  3. Prior genetic diagnosis of DEB due to mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Corneal abrasion frequency

    Frequency of corneal abrasion symptoms

    Time frame: Baseline through up to 1 year

Secondary outcomes

  1. Epidermolysis Bullosa Eye Disease Index Symptom Score

    Symptom score for Epidermolysis Bullosa related eye problems, 0 to 30 (higher score indicates worse symptoms)

    Time frame: Baseline through up to 1 year

07

Study locations

1 of 1 sites recruiting
  • Krystal Biotech
    Pittsburgh, Pennsylvania 15203, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Dec 2025, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 20, 2024
StartActual
Aug 2, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06563414
Lead sponsor
Krystal Biotech, Inc.
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Aug 2, 2024
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jul 2, 2025

Study contacts

David Chien, MD
Contact
dchien@krystalbio.com
412-586-5830
Brittani Agostini, RN, CCRC
Contact
bagostini@krystalbio.com
412-586-5830

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion